Senate Vote Delays Federal Hemp THC Ban, Setting Up New Fight in the House

The U.S. Senate voted Friday night to keep a proposed one-month delay of most new federal restrictions on hemp-derived THC products.

An amendment that would have removed the delay and preserved the original Nov. 12 deadline failed 32-66. The Senate then passed the broader continuing resolution, a temporary government funding bill, early Saturday with the extension intact. If enacted, most of the restrictions would instead take effect Dec. 11, 2026.

Congress approved the restrictions last November to remove many intoxicating hemp products from the federally legal market.

The delay is not final. The House still has to act on the Senate legislation, making it the next battleground over whether the restrictions take effect in November or are pushed into December.

Dissappointed

The U.S. Cannabis Roundtable, which represents major state-licensed cannabis operators, opposed delaying the restrictions and has argued that intoxicating hemp products have been allowed to compete with regulated cannabis without comparable taxation, testing and consumer-protection requirements.

Following the Senate vote, USCR said it was “disappointed” with the outcome and pointed toward the House as the next stage of the debate.

“During the August recess, House members will have the opportunity to hear directly from their constituents on whether unregulated and synthetic hemp products should be widely available for sale, including to minors,” the organization said.

The regulated cannabis industry’s position has placed it alongside groups that normally oppose broader marijuana reform, highlighting how the hemp debate has disrupted traditional political coalitions around cannabis policy.

Hemp advocates, meanwhile, have argued that Congress should establish a federal regulatory system for intoxicating cannabinoid products rather than effectively eliminate much of the existing market.

Not Every Hemp Restriction Would Be Delayed

The Senate language does not simply postpone every provision of the law.

According to reporting on the legislation, the continuing resolution preserves the Nov. 12 effective date for certain synthetic cannabinoids that cannot be naturally produced by the cannabis plant.

Cannabinoids capable of occurring naturally in Cannabis sativa, even at very low concentrations, may be treated differently from compounds that cannot naturally occur in the plant.

That leaves Congress wrestling not only with whether intoxicating hemp should remain legal, but with where to draw the line between naturally occurring cannabinoids, converted cannabinoids, and fully synthetic products.

The Fight Now Moves to the House

The Senate vote does not resolve the underlying dispute.

Instead, it potentially buys lawmakers roughly another month while preserving the broader federal restrictions Congress approved last year.

For licensed cannabis operators, the issue has direct competitive implications. State-regulated marijuana companies generally operate under extensive licensing, testing, taxation and distribution requirements, while hemp-derived THC products have reached consumers through a substantially different federal and state regulatory framework.

For hemp businesses, the stakes are equally high. Without congressional intervention or a replacement regulatory framework, the forthcoming federal definition could remove a significant portion of today’s intoxicating hemp products from the legal market.

The next question is whether the House accepts the Senate’s temporary extension.

If it does, the industry’s November deadline becomes a December deadline.

What happens during that additional month could determine whether Congress ultimately moves toward regulation, prohibition, or another temporary compromise.